Clinical Trials Sponsored by Sanofi Pasteur, a Sanofi Company

Total 1044 results

Sanofi Pasteur, a Sanofi Company

Completed

Database Surveillance Safety Study of PENTACEL® Vaccine

Pertussis | Tetanus | Diphtheria | Haemophilus Influenzae

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia

Meningococcal Infections | Neisseria Meningitidis

Saudi Arabia
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar

Streptococcus Pneumoniae

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines

Japanese Encephalitis | Hepatitis A

Thailand, Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®

Healthy | Infant

Germany
Sanofi Pasteur, a Sanofi Company

Completed

Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen

Rabies

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine

Meningitis | Meningococcal Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers

Japanese Encephalitis | Measles | Rubella | Mumps

Taiwan
Sanofi Pasteur, a Sanofi Company

Completed

Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children

Meningitis | Meningococcal Disease

China
Sanofi Pasteur, a Sanofi Company

Completed

Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.

Hepatitis B | Pertussis | Tetanus | Diphtheria | Haemophilus Influenzae Type b

Peru, Mexico
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immune Response of Different Pediatric Combination Vaccines.

Pertussis | Diphtheria | Polio

United States
Sanofi Pasteur, a Sanofi Company

Completed

Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®

Meningitis | Meningococcal Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine

Pertussis | Tetanus | Diphtheria | Meningitis | Meningococcemia

United States
Sanofi Pasteur, a Sanofi Company

Terminated

Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults

Meningitis | Meningococcemia

United Kingdom
Sanofi Pasteur, a Sanofi Company

Terminated

Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive

HIV Infections | Smallpox

United States
Sanofi Pasteur, a Sanofi Company

Withdrawn

Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)

Atopic Dermatitis | Smallpox

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety of Imovax Polio in Chinese Infants and Children

Poliomyelitis

China
Sanofi Pasteur, a Sanofi Company

Completed

Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine

Smallpox
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly

Poliomyelitis

Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Verorab™ in Indian Population

Rabies

India
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years

Influenza | Swine-origin A/H1N1 Influenza

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults

Influenza | Orthomyxoviridae Infections

Australia
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

France
Sanofi Pasteur, a Sanofi Company

Completed

Influenza Vaccine Revaccination in Ambulatory Elderly Subjects

Influenza | Myxovirus Infection | Orthomyxovirus Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants

Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b

Argentina
Sanofi Pasteur, a Sanofi Company

Completed

Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine

Pertussis | Tetanus | Diphtheria

United States, Canada
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™

Hepatitis B | Pertussis | Tetanus | Diphtheria | Haemophilus Influenzae Type b

Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants

Hepatitis B | Pertussis | Tetanus | Diphtheria | Influenza

Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Safety of a Second Dose of Biken's Varicella Vaccine

Varicella

Argentina
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Study of SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan

Poliomyelitis | Polio

Japan
Sanofi Pasteur, a Sanofi Company

Recruiting

Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (CORAL)

RSV Immunization

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Recruiting

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

Influenza Immunization

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Recruiting

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

Acne

United States
Sanofi Pasteur, a Sanofi Company

Recruiting

Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers

Healthy Volunteers | Meningococcal Immunisation

Czechia, Denmark, Finland, Germany, Poland, Romania
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older

Healthy Volunteers | Respiratory Syncytial Virus Infection

Australia, Dominican Republic, Honduras
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

Healthy Volunteers | Respiratory Syncytial Virus Infection | Human Metapneumovirus

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (MEQ00064)

Healthy Volunteers | Meningococcal Immunisation

South Africa, India
Sanofi Pasteur, a Sanofi Company

Recruiting

Dengvaxia US Pregnancy Registry (DNG00044)

Dengue Virus Infection

Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.

Influenza Immunization

United States, Poland, Spain, Czechia
Sanofi Pasteur, a Sanofi Company

Completed

Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in Vietnam

Healthy Volunteers | Meningococcal Infection

Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above

Influenza Immunization

Australia, United Kingdom
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers

Healthy Volunteers | Meningococcal Immunisation

Spain, Finland, Germany, Hungary
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

Respiratory Syncytial Virus Immunization

United States, Australia, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

Influenza Immunization

Puerto Rico, United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23

Influenza (Healthy Volunteers)

Germany, Finland
Sanofi Pasteur, a Sanofi Company

Completed

Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris (OREA)

Acne Vulgaris | Acne

Germany

3

Subscribe